• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study.
Conclusions: SGLT2i improved cardiometabolic parameters in Thai adults, clinically, confirming findings in controlled trials. PMID: 32776785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 13, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Sodium ‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
ConclusionsSGLT2 inhibitors are an exciting addition to the list of available agents for T2DM, and may be suitable for various types of patients who need additional glycaemic control.
Source: International Journal of Clinical Practice - March 1, 2017 Category: Internal Medicine Authors: Paresh Dandona, Ajay Chaudhuri Tags: REVIEW ARTICLE Source Type: research